Intermittent Granulocyte and Monocyte Apheresis Versus Mercaptopurine for Maintaining Remission of Ulcerative Colitis: A Pilot Study

Atsushi Sakuraba, Toshiro Sato, Yuichi Morohoshi, Katsuyoshi Matsuoka, Susumu Okamoto, Nagamu Inoue, Hiromasa Takaishi, Haruhiko Ogata, Yasushi Iwao, Toshifumi Hibi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The effect of granulocyte and monocyte adsorption apheresis (GMA) on prevention of relapse of ulcerative colitis (UC) is not clear. This was a pilot open-labeled, prospective, randomized, unblinded study to compare the tolerability and efficacy of intermittent GMA (once every 2weeks) with mercaptopurine to maintain remission of UC. Twenty-one patients with UC, who had achieved remission by induction therapies were randomly assigned to receive either intermittent GMA (N=10) or oral mercaptopurine (0.5mg/kg per day; N=11). The study period was 24months. The rate of the patients maintaining remission and the incidences of adverse effects were compared between the two groups. At 24months, seven of 10 patients (70.0%) on intermittent GMA and seven of 11 patients (63.6%, P=1.00) on oral mercaptopurine were still in remission. Three patients relapsed in each group. One patient taking mercaptopurine, but none receiving intermittent GMA, dropped out because of adverse effects. Intermittent therapy with GMA was well tolerated and a substantial proportion of patients maintained remission. Intermittent GMA therapy in maintaining remission of UC merits further investigation.

Original languageEnglish
Pages (from-to)213-218
Number of pages6
JournalTherapeutic Apheresis and Dialysis
Volume16
Issue number3
DOIs
Publication statusPublished - 2012 Jun

Fingerprint

6-Mercaptopurine
Blood Component Removal
Ulcerative Colitis
Granulocytes
Adsorption
Monocytes
Remission Induction
Secondary Prevention
Therapeutics
Incidence

Keywords

  • Granulocyte and monocyte adsorption apheresis
  • Maintenance treatment
  • Mercaptopurine
  • Ulcerative colitis

ASJC Scopus subject areas

  • Hematology
  • Nephrology

Cite this

Intermittent Granulocyte and Monocyte Apheresis Versus Mercaptopurine for Maintaining Remission of Ulcerative Colitis : A Pilot Study. / Sakuraba, Atsushi; Sato, Toshiro; Morohoshi, Yuichi; Matsuoka, Katsuyoshi; Okamoto, Susumu; Inoue, Nagamu; Takaishi, Hiromasa; Ogata, Haruhiko; Iwao, Yasushi; Hibi, Toshifumi.

In: Therapeutic Apheresis and Dialysis, Vol. 16, No. 3, 06.2012, p. 213-218.

Research output: Contribution to journalArticle

@article{be1d8eacd72a4300adaa77c71ef45d3b,
title = "Intermittent Granulocyte and Monocyte Apheresis Versus Mercaptopurine for Maintaining Remission of Ulcerative Colitis: A Pilot Study",
abstract = "The effect of granulocyte and monocyte adsorption apheresis (GMA) on prevention of relapse of ulcerative colitis (UC) is not clear. This was a pilot open-labeled, prospective, randomized, unblinded study to compare the tolerability and efficacy of intermittent GMA (once every 2weeks) with mercaptopurine to maintain remission of UC. Twenty-one patients with UC, who had achieved remission by induction therapies were randomly assigned to receive either intermittent GMA (N=10) or oral mercaptopurine (0.5mg/kg per day; N=11). The study period was 24months. The rate of the patients maintaining remission and the incidences of adverse effects were compared between the two groups. At 24months, seven of 10 patients (70.0{\%}) on intermittent GMA and seven of 11 patients (63.6{\%}, P=1.00) on oral mercaptopurine were still in remission. Three patients relapsed in each group. One patient taking mercaptopurine, but none receiving intermittent GMA, dropped out because of adverse effects. Intermittent therapy with GMA was well tolerated and a substantial proportion of patients maintained remission. Intermittent GMA therapy in maintaining remission of UC merits further investigation.",
keywords = "Granulocyte and monocyte adsorption apheresis, Maintenance treatment, Mercaptopurine, Ulcerative colitis",
author = "Atsushi Sakuraba and Toshiro Sato and Yuichi Morohoshi and Katsuyoshi Matsuoka and Susumu Okamoto and Nagamu Inoue and Hiromasa Takaishi and Haruhiko Ogata and Yasushi Iwao and Toshifumi Hibi",
year = "2012",
month = "6",
doi = "10.1111/j.1744-9987.2012.01064.x",
language = "English",
volume = "16",
pages = "213--218",
journal = "Therapeutic Apheresis and Dialysis",
issn = "1744-9979",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Intermittent Granulocyte and Monocyte Apheresis Versus Mercaptopurine for Maintaining Remission of Ulcerative Colitis

T2 - A Pilot Study

AU - Sakuraba, Atsushi

AU - Sato, Toshiro

AU - Morohoshi, Yuichi

AU - Matsuoka, Katsuyoshi

AU - Okamoto, Susumu

AU - Inoue, Nagamu

AU - Takaishi, Hiromasa

AU - Ogata, Haruhiko

AU - Iwao, Yasushi

AU - Hibi, Toshifumi

PY - 2012/6

Y1 - 2012/6

N2 - The effect of granulocyte and monocyte adsorption apheresis (GMA) on prevention of relapse of ulcerative colitis (UC) is not clear. This was a pilot open-labeled, prospective, randomized, unblinded study to compare the tolerability and efficacy of intermittent GMA (once every 2weeks) with mercaptopurine to maintain remission of UC. Twenty-one patients with UC, who had achieved remission by induction therapies were randomly assigned to receive either intermittent GMA (N=10) or oral mercaptopurine (0.5mg/kg per day; N=11). The study period was 24months. The rate of the patients maintaining remission and the incidences of adverse effects were compared between the two groups. At 24months, seven of 10 patients (70.0%) on intermittent GMA and seven of 11 patients (63.6%, P=1.00) on oral mercaptopurine were still in remission. Three patients relapsed in each group. One patient taking mercaptopurine, but none receiving intermittent GMA, dropped out because of adverse effects. Intermittent therapy with GMA was well tolerated and a substantial proportion of patients maintained remission. Intermittent GMA therapy in maintaining remission of UC merits further investigation.

AB - The effect of granulocyte and monocyte adsorption apheresis (GMA) on prevention of relapse of ulcerative colitis (UC) is not clear. This was a pilot open-labeled, prospective, randomized, unblinded study to compare the tolerability and efficacy of intermittent GMA (once every 2weeks) with mercaptopurine to maintain remission of UC. Twenty-one patients with UC, who had achieved remission by induction therapies were randomly assigned to receive either intermittent GMA (N=10) or oral mercaptopurine (0.5mg/kg per day; N=11). The study period was 24months. The rate of the patients maintaining remission and the incidences of adverse effects were compared between the two groups. At 24months, seven of 10 patients (70.0%) on intermittent GMA and seven of 11 patients (63.6%, P=1.00) on oral mercaptopurine were still in remission. Three patients relapsed in each group. One patient taking mercaptopurine, but none receiving intermittent GMA, dropped out because of adverse effects. Intermittent therapy with GMA was well tolerated and a substantial proportion of patients maintained remission. Intermittent GMA therapy in maintaining remission of UC merits further investigation.

KW - Granulocyte and monocyte adsorption apheresis

KW - Maintenance treatment

KW - Mercaptopurine

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84861335403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861335403&partnerID=8YFLogxK

U2 - 10.1111/j.1744-9987.2012.01064.x

DO - 10.1111/j.1744-9987.2012.01064.x

M3 - Article

C2 - 22607563

AN - SCOPUS:84861335403

VL - 16

SP - 213

EP - 218

JO - Therapeutic Apheresis and Dialysis

JF - Therapeutic Apheresis and Dialysis

SN - 1744-9979

IS - 3

ER -